Gm884 Activators
Leucine Rich Repeat Containing 37 (LRRC37) activators are a diverse group of bioactive compounds that share the common feature of modulating the activity of proteins containing leucine-rich repeat (LRR) domains, specifically the LRRC37 protein. The leucine-rich repeat is a structural motif involved in protein-protein interactions and is characterized by a typically 20-30 amino acid sequence rich in leucine residues. These sequences form a structure that presents a versatile platform for the formation of protein complexes. Activators of LRRC37 can function through various mechanisms, often involving the modulation of signaling pathways that lead to post-translational modifications of proteins, particularly phosphorylation. Such compounds can affect the activity of LRRC37 by altering its conformation, localization, stability, or interactions with other proteins and molecules within the cell. This alteration is typically achieved through the activation or inhibition of specific enzymes that directly or indirectly target LRRC37 or its associated pathways.
The chemical entities that act as LRRC37 activators can be small organic molecules, peptides, or other natural products that permeate the cellular membrane and exert their effects intracellularly. These activators often target key regulatory proteins such as kinases and phosphatases, which play critical roles in cellular signaling networks. For instance, compounds like forskolin and 8-CPT-cAMP enhance LRRC37 function by increasing the cellular levels of cyclic AMP (cAMP), a second messenger that activates protein kinase A (PKA), leading to the phosphorylation of target proteins. On the other hand, ionomycin and thapsigargin elevate intracellular calcium levels, triggering calcium-dependent signaling pathways, including the activation of calmodulin-dependent kinase (CaMK), which may also result in phosphorylation events that affect LRRC37. Other compounds, such as okadaic acid, act indirectly by inhibiting protein phosphatases, thereby leading to a higher phosphorylation state within the cell, which can modulate the activity of proteins, including LRRC37.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-CPT-cAMP | 93882-12-3 | sc-201569 sc-201569A | 20 mg 100 mg | $87.00 $316.00 | 19 | |
8-CPT-cAMP is a cell-permeable cAMP analog that activates PKA. The activated PKA can phosphorylate downstream targets, enhancing the activity of leucine rich repeat containing 37 by altering its conformation or stability. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels, thereby activating calcium-dependent signaling pathways which include calmodulin-dependent kinase (CaMK) that may phosphorylate and enhance leucine rich repeat containing 37 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the SERCA pump, leading to increased cytosolic calcium. Elevated calcium can activate CaMK, which may then lead to the activation of leucine rich repeat containing 37 through phosphorylation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, which results in increased phosphorylation levels within the cell. This can indirectly enhance leucine rich repeat containing 37 activity by increasing the phosphorylated state of proteins that interact with or regulate it. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits phosphodiesterases, leading to higher cAMP levels, and thus activating PKA. Activated PKA can phosphorylate proteins, potentially enhancing the activity of leucine rich repeat containing 37 through phosphorylation-dependent changes. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3), which can lead to the activation of downstream proteins that may interact with or regulate leucine rich repeat containing 37, enhancing its activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a PKC inhibitor that can lead to compensatory cellular responses, potentially enhancing leucine rich repeat containing 37 activity through alternative signaling pathways that are PKC-independent. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates PKC, which can lead to the phosphorylation of target proteins, potentially enhancing leucine rich repeat containing 37 activity through PKC-mediated signaling pathways. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin acts as a protein synthesis inhibitor that activates the JNK signaling pathway, potentially enhancing leucine rich repeat containing 37 activity through stress-activated protein kinase pathways. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
Bay K8644 is a calcium channel agonist that can increase intracellular calcium, activating calcium-dependent signaling pathways, potentially enhancing leucine rich repeat containing 37 activity. | ||||||